FDA launches a six-month safety study of the abortion pill mifepristone, a step toward restricting mail and telehealth access that antiabortion groups demanded.
Results land after the midterms
Read the full story at The Wall Street Journal [gift link]
From the June 4, 2026 GovBrief, every story that day in one place.